Towards personalized prostate cancer screening

Abstract

The value of the prostate-specific antigen (PSA) in prostate cancer (PCa) screening is controversial. Contradictory results have been reported in the literature as to whether PSA-based screening reduces mortality. Also, some of the studies published are methodologically flawed. However, evidence consistently demonstrates that screening programs results in the identification of patients with indolent prostatic tumors which rate has increased.

Keywords

• prostate-specific antigen (psa)
• screening
• prostate cancer
• phi
• 4kscore